Long interspersed nuclear element-1 integration site (LINE-1 integration site)

A specific genomic locus compatible with LINE-1-mediated integration refers to a site in the human genome where the Long Interspersed Nuclear Element-1 (LINE-1 or L1) retrotransposon can insert its DNA sequence. LINE-1 is an autonomous retroelement that utilizes a copy-and-paste mechanism involving an RNA intermediate and the protein machinery ORF1p and ORF2p. The integration process, known as target-primed reverse transcription (TPRT), typically targets a degenerate consensus sequence, most commonly 5'-TTTT/A-3', though integration can be influenced by local chromatin structure and DNA accessibility. In a therapeutic context, identifying specific, 'safe' genomic loci for LINE-1-mediated integration is a key goal for gene therapy platforms, such as those being developed by companies like Tessera Therapeutics, which aim to use mobile genetic elements for precise gene addition or editing. While LINE-1 activity is a driver of genetic diversity and evolution, aberrant integration into functional genes can lead to diseases such as cancer or hemophilia by disrupting gene regulation or coding sequences. Consequently, the selection of integration sites is a critical safety factor in the development of retrotransposon-based genetic medicines to avoid off-target effects and insertional mutagenesis.

Other names

L1 integration siteLINE-1 target siteRetrotransposon integration locusGenomic safe harbor for LINE-1Target-primed reverse transcription site

LINE-1-mediated integration occurs via target-primed reverse transcription (TPRT), where the LINE-1 encoded endonuclease (ORF2p) cleaves a specific genomic sequence (typically 5'-TTTT/A-3') to create a primer for reverse transcription of the LINE-1 RNA directly into the host DNA.